SavedAdd your journal

Journals / Tıp Fakültesi Klinikleri Dergisi / 2026 / Cilt: 9 Sayı: 2

Emerging Roles of miR-146a-5p in Multiple Sclerosis: Evidence from Recent Studies

Multiple Sklerozda miR-146a-5p’nin Ortaya Çıkan Rolleri: Güncel Çalışmalardan Kanıtlar

Ahmed Mohamed(ISTANBUL MEDENIYET UNIVERSITY, FACULTY OF ENGINEERING AND NATURAL SCIENCES, DEPARTMENT OF MOLECULAR BIOLOGY AND GENETICS)0009-0000-4324-8506
Rahaf A I Altartoor(ISTANBUL MEDENIYET UNIVERSITY, FACULTY OF ENGINEERING AND NATURAL SCIENCES, DEPARTMENT OF MOLECULAR BIOLOGY AND GENETICS)0009-0007-8232-8382
Sarah Alosman(ISTANBUL MEDENIYET UNIVERSITY, FACULTY OF ENGINEERING AND NATURAL SCIENCES, DEPARTMENT OF MOLECULAR BIOLOGY AND GENETICS)0009-0007-4558-247X
Fatma Sağır(ISTANBUL MEDENIYET UNIVERSITY, FACULTY OF ENGINEERING AND NATURAL SCIENCES, DEPARTMENT OF MOLECULAR BIOLOGY AND GENETICS)0000-0002-4086-8459
Pages
101–109
Publication Date
2026-07-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Future research should focus on elucidating its precise mechanisms across different cellular contexts and developing targeted delivery systems to translate these findings into effective miR-146a-5p-based interventions for MS.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Multiple sclerosis is a complex neuroimmune disorder characterized by chronic inflammation, demyelination, and neurodegeneration.
📊
Key Findings & Data:Among the various molecular players, microRNA-146a-5p has emerged as a critical, albeit complex, regulator of the neuroimmune landscape in MS.
💡
Conclusion & Impact:Future research should focus on elucidating its precise mechanisms across different cellular contexts and developing targeted delivery systems to translate these findings into effective miR-146a-5p-based interventions for MS.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Multipl Skleroz · miR-146a-5p · biyobelirteç

Abstract

Multiple sclerosis is a complex neuroimmune disorder characterized by chronic inflammation, demyelination, and neurodegeneration. Among the various molecular players, microRNA-146a-5p has emerged as a critical, albeit complex, regulator of the neuroimmune landscape in MS. This review synthesizes recent evidence highlighting the dual role of miR-146a-5p, which primarily functions as an anti-inflammatory agent but can also contribute to pathology in a cell-type and context-dependent manner. Its expression is dynamically regulated in the central nervous system , cerebrospinal fluid, and blood, correlating with disease activity, treatment response, and clinical metrics such as the Expanded Disability Status Scale. We explore its compartmentalized dysregulation, notably in active gadolinium-enhancing lesions, and its potential as a sensitive diagnostic and prognostic biomarker. The involvement of miR-146a-5p in key cellular processes—including microglial activation, oligodendrocyte maturation, and astrocyte pathology—underscores its therapeutic relevance. Furthermore, we discuss its interaction with environmental factors like Vitamin D and its role in exosome-mediated intercellular communication. Preclinical studies demonstrating that manipulating miR-146a-5p levels can ameliorate neuroinflammation and promote remyelination solidify its promise as a novel therapeutic target. Future research should focus on elucidating its precise mechanisms across different cellular contexts and developing targeted delivery systems to translate these findings into effective miR-146a-5p-based interventions for MS.

Özet

Multipl skleroz, kronik inflamasyon, demiyelinizasyon ve nörodejenerasyon ile karakterize karmaşık bir nöroimmün hastalıktır. Çeşitli moleküler düzenleyiciler arasında, mikroRNA-146a-5p, MS’te nöroimmün ortamın kritik ancak karmaşık bir düzenleyicisi olarak öne çıkmıştır. Bu derleme, esas olarak anti-inflamatuvar bir düzenleyici olarak işlev görmesine rağmen, hücre tipine ve bağlama bağlı olarak patolojik süreçlere de katkıda bulunabilen miR-146a-5p’nin çift yönlü rolünü vurgulayan güncel kanıtları bir araya getirmektedir. miR-146a-5p’nin ekspresyonu merkezi sinir sistemi, beyin omurilik sıvısı ve kanda dinamik olarak düzenlenmekte; hastalık aktivitesi, tedavi yanıtı ve Genişletilmiş Özürlülük Durum Ölçeği (EDSS) gibi klinik göstergelerle ilişki göstermektedir. Aktif gadolinyumla zenginleşmiş lezyonlarda belirgin olan bölgesel düzensizliği ve duyarlı bir tanısal ve prognostik biyobelirteç olarak potansiyeli ele alınmıştır. miR-146a-5p’nin mikroglia aktivasyonu, oligodendrosit olgunlaşması ve astrosit patolojisi gibi temel hücresel süreçlerdeki rolü, terapötik önemini vurgulamaktadır. Ayrıca, D vitamini gibi çevresel faktörlerle etkileşimi ve eksozom aracılı hücreler arası iletişimdeki rolü de tartışılmıştır. miR-146a-5p düzeylerinin düzenlenmesinin nöroinflamasyonu hafiflettiğini ve remiyelinizasyonu desteklediğini gösteren preklinik çalışmalar, bu molekülün yeni bir terapötik hedef olarak potansiyelini pekiştirmektedir. Gelecekteki araştırmaların, farklı hücresel bağlamlarda miR-146a-5p’nin kesin etki mekanizmalarını aydınlatmaya ve bu bulguları MS için etkili miR-146a-5p temelli tedavilere dönüştürebilecek hedefe yönelik taşıma sistemleri geliştirmeye odaklanması gerekmektedir.

🔖

Cite This Article

Mohamed, A., Altartoor, R. A. I., Alosman, S., Sağır, F. (2026). Emerging Roles of miR-146a-5p in Multiple Sclerosis: Evidence from Recent Studies. Tıp Fakültesi Klinikleri Dergisi, Cilt: 9 Sayı: 2, 101–109. https://ajindex.com/articles/1602058

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (61)

  1. Turk, A., Maver, A., Juvan, P., Drulović, J., Mesaroš, Š., Novaković, I.,. & Peterlin, B. (2025). Increased burden of rare variants in GWAS associated genes in familial multiple sclerosis. Scientific reports, 15(1), 21200.
  2. Muzio, L., & Perego, J. (2024). CNS resident innate immune cells: Guardians of CNS homeostasis. International Journal of Molecular Sciences, 25(9), 4865.
  3. Maghbooli, Z., Sayahpour, F. A., Varzandi, T., Masoumi, M. R., & Sahraian, M. A. (2025). The interplay between endoplasmic reticulum stress and inflammation in multiple sclerosis. Scientific Reports, 15(1), 22916.
  4. Cree, B. A., Arnold, D. L., Chataway, J., Chitnis, T., Fox, R. J., Pozo Ramajo, A.,. & Lassmann, H. (2021). Secondary progressive multiple sclerosis: new insights. Neurology, 97(8), 378-388.
  5. Motyer, A., Jackson, S., Yang, B., Harliwong, I., Tian, W., Shiu, W. I. A.,. & Rubio, J. P. (2025). Neuronal somatic mutations are increased in multiple sclerosis lesions. Nature Neuroscience, 28(4), 757- 765.
  6. Harvey, L. M., Frédérick, P. M., Gudipati, R. K., Michaud, P., Houle, F., Young, D.,. & Simard, M. J. (2025). Dipeptidyl peptidase DPF-3 is a gatekeeper of microRNA Argonaute compensation in animals. Nature communications, 16(1), 2738.
  7. Soyocak, A. (2018). MikroRNA Polimorfizmleri ve Kanser. Tıp Fakültesi Klinikleri Dergisi, 1(1), 1-18.
  8. Szabo, G., & Bala, S. (2013). MicroRNAs in liver disease. Nature reviews Gastroenterology & hepatology, 10(9), 542-552.
  9. Rawat, M., Govindappa, P. K., Gupta, Y., & Ma, T. Y. (2025). MicroRNA in intestinal tight junction regulation. npj Gut and Liver, 2(1), 11.
  10. BioRender. BioRender.com. Available at: https://www.biorender.com/
  11. Sağır, F. (2023). Multipl skleroz hastalığında miRNA'ların biyobelirteç olarak araştırılması (Tez No. 806187) [Doktora tezi, İstanbul Üniversitesi]. YÖK Ulusal Tez Merkezi.
  12. Nemeth, K., Bayraktar, R., Ferracin, M., & Calin, G. A. (2024). Non-coding RNAs in disease: from mechanisms to therapeutics. Nature Reviews Genetics, 25(3), 211-232.
  13. Aslani, M., Mortazavi-Jahromi, S. S., & Mirshafiey, A. (2021). Efficient roles of miR146a in cellular and molecular mechanisms of neuroinflammatory disorders: an effectual review in neuroimmunology. Immunology Letters, 238, 1-20.
  14. Xiong, J. R., Yan, Z. Y., Shi, M. Q., Zhou, G., Zhang, J. H., Xu, J.,. & Tang, H. M. (2025). miR-146a regulates neuroinflammation and immune cell function in neurodegenerative diseases. Current Medical Science, 45(4), 725-744.
  15. Ramasamy, I. (2020). Vitamin D metabolism and guidelines for vitamin D supplementation. The Clinical Biochemist Reviews, 41(3), 103.
  16. Al-Shammri, S., Chattopadhyay, A., & Raghupathy, R. (2025). Vitamin D supplementation mediates a shift toward anti-inflammatory cytokine response in multiple sclerosis. Medical Principles and Practice, 34(4), 360-368.
  17. Milanifard, M., Mehrabi, S., Ahadw, R., Nabiuni, M., Souteh, S. A., & Joghataei, M. T. (2024). Evaluation relationship between vitamin D Receptor and clinical and inflammatory factors in patients with relapsing-remitting multiple sclerosis. European Journal of Translational Myology, 34(4), 12939.
  18. Mohammadi-Kordkhayli, M., Sahraian, M. A., Ghorbani, S., Mansouri, F., Talebi, F., Noorbakhsh, F., & Saboor-Yaraghi, A. A. (2023). Vitamins A and D enhance the expression of Ror-γ-Targeting MiRNAs in a mouse model of multiple sclerosis. Molecular Neurobiology, 60(10), 5853-5865.
  19. Saridas, F., Tezcan Unlu, H., Cecener, G., Egeli, U., Sabour Takanlou, M., Sabour Takanlou, L.,. & Taskapilioglu, O. (2022). The expression and prognostic value of miR-146a and miR-155 in Turkish patients with multiple sclerosis. Neurological Research, 44(3), 217-223.
  20. Saade, C., Bou-Fakhredin, R., Yousem, D. M., Asmar, K., Naffaa, L., & El-Merhi, F. (2018). Gadolinium and multiple sclerosis: vessels, barriers of the brain, and glymphatics. American Journal of Neuroradiology, 39(12), 2168-2176.
  21. Mohammadinasr, M., Montazersaheb, S., Hosseini, V., Kahroba, H., Talebi, M., Molavi, O.,. & Hejazi, M. S. (2024). Epstein- Barr virus-encoded BART9 and BART15 miRNAs are elevated in exosomes of cerebrospinal fluid from relapsing remitting multiple sclerosis patients. Cytokine, 179, 156624.
  22. Pavlovic, I., Axling, F., Nazir, F. H., Müller, M., Wiberg, A., & Burman, J. (2024). Micro-RNA Signature in CSF Before and After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis. Neurology: Neuroimmunology & Neuroinflammation, 12(1), e200345.
  23. Muñoz-San Martín, M., Reverter, G., Robles- Cedeño, R., Buxò, M., Ortega, F. J., Gómez, I.,. & Ramió-Torrentà, L. (2019). Analysis of miRNA signatures in CSF identifies upregulation of miR-21 and miR- 146a/b in patients with multiple sclerosis and active lesions. Journal of neuroinflammation, 16(1), 220.
  24. Casanova, I., Domínguez-Mozo, M. I., De Torres, L., Aladro-Benito, Y., GarcíaMartínez, Á., Gómez, P.,. & Álvarez-Lafuente, R. (2023). MicroRNAs associated with disability progression and clinical activity in multiple sclerosis patients treated with glatiramer acetate. Biomedicines, 11(10), 2760.
  25. Dominguez-Mozo, M. I., Casanova, I., De Torres, L., Aladro-Benito, Y., Perez-Perez, S., Garcia-Martínez, A.,. & Alvarez- Lafuente, R. (2022). MicroRNA expression and its association with disability and brain atrophy in multiple sclerosis patients treated with glatiramer acetate. Frontiers in immunology, 13, 904683.
  26. Giuliani, A., Lattanzi, S., Ramini, D., Graciotti, L., Danni, M. C., Procopio, A. D.,. & Sabbatinelli, J. (2021). Potential prognostic value of circulating inflamma-mi- R146a-5p and miR-125a-5p in relapsingremitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 54, 103126.
  27. Unlu, H. T., Saridas, F., Taskapilioglu, O., Cecener, G., Egeli, U., Turan, O. F.,. & Zarifoglu, M. (2023). Investigation of miR- 146a expression profiles in fecal samples of patients with multiple sclerosis for early diagnosis and treatment. Neurological Sciences and Neurophysiology, 40(2), 81-87.
  28. Torres-Iglesias, G., López-Molina, M., Ayala-Suárez, R., Egido, B., Laso-García, F., Chamorro, B.,. & Otero Ortega, L. (2025). Extracellular vesicle-derived microRNAs as a biomarker for therapeutic response in multiple sclerosis. Neurology: Neuroimmunology & Neuroinflammation, 12(4), e200420.
  29. Berry, K., Wang, J., & Lu, Q. R. (2020). Epigenetic regulation of oligodendrocyte myelination in developmental disorders and neurodegenerative diseases. F1000Research 9: F1000 Faculty Rev-105.
  30. Zhang, J., Zhang, Z. G., Lu, M., Zhang, Y., Shang, X., & Chopp, M. (2019). MiR-146a promotes oligodendrocyte progenitor cell differentiation and enhances remyelination in a model of experimental autoimmune encephalomyelitis. Neurobiology of disease, 125, 154-162.
  31. Martin, N. A., Molnar, V., Szilagyi, G. T., Elkjaer, M. L., Nawrocki, A., & Okarmus, J. (2018). Experimental Demyelination and Axonal Loss Are Reduced in MicroRNA146a Deficient Mice. Front Immunol. 2018; 9: 490.
  32. Mado, H., Adamczyk-Sowa, M., & Sowa, P. (2023). Role of microglial cells in the pathophysiology of MS: synergistic or antagonistic?. International Journal of Molecular Sciences, 24(3), 1861.
  33. Guo, S., Wang, H., & Yin, Y. (2022). Microglia polarization from M1 to M2 in neurodegenerative diseases. Frontiers in aging neuroscience, 14, 815347.
  34. Martin, N. A., Hyrlov, K. H., Elkjaer, M. L., Thygesen, E. K., Wlodarczyk, A., Elbaek, K. J.,. & Illes, Z. (2020). Absence of miRNA-146a differentially alters microglia function and proteome. Frontiers in Immunology, 11, 1110.
  35. Jia, J., Liu, C., Han, Y., Han, H., Zhong, M., & Gao, Y. (2020). miR-146a alleviates the apoptosis of hippocampal neurons induced by microglia activation via targeting TRAF6. Human & Experimental Toxicology, 39(12), 1650-1660.
  36. Rao, V. T., Fuh, S. C., Karamchandani, J. R., Woulfe, J. M., Munoz, D. G., Ellezam, B.,. & Ludwin, S. K. (2019). Astrocytes in the pathogenesis of multiple sclerosis: an in situ microRNA study. Journal of Neuropathology & Experimental Neurology, 78(12), 1130-1146.
  37. Rao, V., Ludwin, S., Fuh, S. C., Minderman, M., Saiaya, R., Moore, C.,. & Antel, J. (2016). Contrasting In Situ and In Vitro Expression of miR-155 and miR-146a in Astrocytes in Context of Multiple Sclerosis (MS)(P3. 009). Neurology, 86(16_supplement), P3-009.
  38. Galloway, D. A., Williams, J. B., & Moore, C. S. (2017). Effects of fumarates on inflammatory human astrocyte responses and oligodendrocyte differentiation. Annals of Clinical and Translational Neurology, 4(6), 381-391.
  39. Barbosa, M., Gomes, C., Sequeira, C., Gonçalves-Ribeiro, J., Pina, C. C., Carvalho, L. A.,. & Brites, D. (2021). Recovery of depleted miR-146a in ALS cortical astrocytes reverts cell aberrancies and prevents paracrine pathogenicity on microglia and motor neurons. Frontiers in cell and developmental biology, 9, 634355.
  40. Thompson, C. E., Loshi, S., Carew, S. J., Berry, T. R., Parsons, M. P., Antel, J. P., & Moore, C. S. (2025). MiR-146b-5p Decreases Cytokine Release From Astrocytes and Preserves Oligodendrocyte Progenitor Cell Complexity During Inflammation. European Journal of Neuroscience, 62(5), e70248.
  41. Hasaniani, N., Nouri, S., Shirzad, M., & Rostami-Mansoor, S. (2024). Potential therapeutic and diagnostic approaches of exosomes in multiple sclerosis pathophysiology. Life Sciences, 347, 122668.
  42. Manna, I., Iaccino, E., Dattilo, V., Barone, S., Vecchio, E., Mimmi, S.,. & Quattrone, A. (2018). Exosome-associated miRNA profile as a prognostic tool for therapy response monitoring in multiple sclerosis patients. The FASEB Journal, 32(8), 42414246.
  43. Huang, X., Liu, X., Zeng, J., Du, P., Huang, X., & Lin, J. (2023). Bone marrow mesenchymal stem cell-derived exosomal microRNA regulates microglial polarization. PeerJ, 11, e16359.
  44. Turk, A., Maver, A., Juvan, P., Drulović, J., Mesaroš, Š., Novaković, I.,. & Peterlin, B. (2025). Increased burden of rare variants in GWAS associated genes in familial multiple sclerosis. Scientific reports, 15(1), 21200.
  45. Cree, B. A., Arnold, D. L., Chataway, J., Chitnis, T., Fox, R. J., Pozo Ramajo, A.,. & Lassmann, H. (2021). Secondary progressive multiple sclerosis: new insights. Neurology, 97(8), 378-388.
  46. Motyer, A., Jackson, S., Yang, B., Harliwong, I., Tian, W., Shiu, W. I. A.,. & Rubio, J. P. (2025). Neuronal somatic mutations are increased in multiple sclerosis lesions. Nature Neuroscience, 28(4), 757- 765.
  47. Harvey, L. M., Frédérick, P. M., Gudipati, R. K., Michaud, P., Houle, F., Young, D.,. & Simard, M. J. (2025). Dipeptidyl peptidase DPF-3 is a gatekeeper of microRNA Argonaute compensation in animals. Nature communications, 16(1), 2738.
  48. Xiong, J. R., Yan, Z. Y., Shi, M. Q., Zhou, G., Zhang, J. H., Xu, J.,. & Tang, H. M. (2025). miR-146a regulates neuroinflammation and immune cell function in neurodegenerative diseases. Current Medical Science, 45(4), 725-744.
  49. Saridas, F., Tezcan Unlu, H., Cecener, G., Egeli, U., Sabour Takanlou, M., Sabour Takanlou, L.,. & Taskapilioglu, O. (2022). The expression and prognostic value of miR-146a and miR-155 in Turkish patients with multiple sclerosis. Neurological Research, 44(3), 217-223.
  50. Mohammadinasr, M., Montazersaheb, S., Hosseini, V., Kahroba, H., Talebi, M., Molavi, O.,. & Hejazi, M. S. (2024). Epstein- Barr virus-encoded BART9 and BART15 miRNAs are elevated in exosomes of cerebrospinal fluid from relapsing remitting multiple sclerosis patients. Cytokine, 179, 156624.
  51. Muñoz-San Martín, M., Reverter, G., Robles- Cedeño, R., Buxò, M., Ortega, F. J., Gómez, I.,. & Ramió-Torrentà, L. (2019). Analysis of miRNA signatures in CSF identifies upregulation of miR-21 and miR- 146a/b in patients with multiple sclerosis and active lesions. Journal of neuroinflammation, 16(1), 220.
  52. Casanova, I., Domínguez-Mozo, M. I., De Torres, L., Aladro-Benito, Y., GarcíaMartínez, Á., Gómez, P.,. & Álvarez-Lafuente, R. (2023). MicroRNAs associated with disability progression and clinical activity in multiple sclerosis patients treated with glatiramer acetate. Biomedicines, 11(10), 2760.
  53. Dominguez-Mozo, M. I., Casanova, I., De Torres, L., Aladro-Benito, Y., Perez-Perez, S., Garcia-Martínez, A.,. & Alvarez- Lafuente, R. (2022). MicroRNA expression and its association with disability and brain atrophy in multiple sclerosis patients treated with glatiramer acetate. Frontiers in immunology, 13, 904683.
  54. Giuliani, A., Lattanzi, S., Ramini, D., Graciotti, L., Danni, M. C., Procopio, A. D.,. & Sabbatinelli, J. (2021). Potential prognostic value of circulating inflamma-mi- R146a-5p and miR-125a-5p in relapsingremitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 54, 103126.
  55. Unlu, H. T., Saridas, F., Taskapilioglu, O., Cecener, G., Egeli, U., Turan, O. F.,. & Zarifoglu, M. (2023). Investigation of miR- 146a expression profiles in fecal samples of patients with multiple sclerosis for early diagnosis and treatment. Neurological Sciences and Neurophysiology, 40(2), 81-87.
  56. Torres-Iglesias, G., López-Molina, M., Ayala-Suárez, R., Egido, B., Laso-García, F., Chamorro, B.,. & Otero Ortega, L. (2025). Extracellular vesicle-derived microRNAs as a biomarker for therapeutic response in multiple sclerosis. Neurology: Neuroimmunology & Neuroinflammation, 12(4), e200420.
  57. Martin, N. A., Hyrlov, K. H., Elkjaer, M. L., Thygesen, E. K., Wlodarczyk, A., Elbaek, K. J.,. & Illes, Z. (2020). Absence of miRNA-146a differentially alters microglia function and proteome. Frontiers in Immunology, 11, 1110.
  58. Rao, V. T., Fuh, S. C., Karamchandani, J. R., Woulfe, J. M., Munoz, D. G., Ellezam, B.,. & Ludwin, S. K. (2019). Astrocytes in the pathogenesis of multiple sclerosis: an in situ microRNA study. Journal of Neuropathology & Experimental Neurology, 78(12), 1130-1146.
  59. Rao, V., Ludwin, S., Fuh, S. C., Minderman, M., Saiaya, R., Moore, C.,. & Antel, J. (2016). Contrasting In Situ and In Vitro Expression of miR-155 and miR-146a in Astrocytes in Context of Multiple Sclerosis (MS)(P3. 009). Neurology, 86(16_supplement), P3-009.
  60. Barbosa, M., Gomes, C., Sequeira, C., Gonçalves-Ribeiro, J., Pina, C. C., Carvalho, L. A.,. & Brites, D. (2021). Recovery of depleted miR-146a in ALS cortical astrocytes reverts cell aberrancies and prevents paracrine pathogenicity on microglia and motor neurons. Frontiers in cell and developmental biology, 9, 634355.
  61. Manna, I., Iaccino, E., Dattilo, V., Barone, S., Vecchio, E., Mimmi, S.,. & Quattrone, A. (2018). Exosome-associated miRNA profile as a prognostic tool for therapy response monitoring in multiple sclerosis patients. The FASEB Journal, 32(8), 42414246.